IPHARMA was authorized to conduct a Phase III clinical trial

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase III clinical trial of the drug АВ5080.


The investigational drug developer is the Chemical Diversity Research Institute.


Protocol № FLU-AV5080-03


The purpose is to assess the efficacy and safety of АВ5080 in patients with simple influenza.

The study will be conducted in 11 clinical sites. Number of patients - 875.



Недавние посты
Архив

© 2021 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon